drugset / Trial / NCT03309241
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
RandomizedSequentialTriple-blindBasic science
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-06882961 in healthy adult subjects. This is the first clinical study of PF-06882961.
Timeline
- Start
- 2017-10-17
- Primary completion
- 2018-02-21
- Completion
- 2018-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danuglipron | Small molecule | 3 mg | Oral |
Indications
No indication recorded.